The BioIntegral Surgical Technology
The BioIntegral Surgical biomodified technology functions to allow growth of the endothelium on all blood contacting surfaces.
• Reduced toxicity
• Enhanced biocompatibility
• Lower rates of infections, adhesions and calcifications4
• Allows for endothelialization, thus enhances patency better than any other vascular graft3,5,8
1. Amir Aboholda, et al., “No-React Detoxification Process: A Superior Anticalcification Method for Bioprostheses.” Ann. Thor. Surg. 62 (1996) 1724-30.
2. Michele Musci, et al. “Surgical therapy in patients with active infective endocarditis: sev- en-year single centre experience in a subgroup of 255 patients treated with the
Shelhigh stentless bioprosthesis,” Eur. J. Card. Surg. 34 (2008) 410-417.
3. Michele Musci, et al. “Further Experience with the “No-React” Bioprosthesis in Patients with Active Infective Endocarditis: 11-Year Single Center Results in 402 Patients”
Eur. J. Card. Surg. 61 (2013) 398-408.
4. Yerebakan, C., et al., “Long-term results of biventricular repair after initial Giessen hy- brid approach for hypoplastic left heart variants,” J. Thor. Card. Surg. 149 (2015).
5. Meduoye, A., Sosnowski, A. and Manuel Galiñanes, “No-React Composite Stentless Aortic Valved Conduit: A Decade of Experience,” Presented at Ten Years Follow-Up
with No-React Heart Valves, Toronto, Canada. (May 2nd, 2010).
6. Proal, A. “Understanding Biofilms,” Bacteriality (2008).
7. Leid, J.G., “Bacterial Biofilms Resist Key Host Defenses,” Am. Soc. Microbio., (2009).
8. Victor O. Morell and Peter A Wearden, Experience With Bovine Pericardium for the Re- construction of the Aortic Arch in Patients Undergoing the Norwood Procedure,“
Ann. Thor. Surg. 84 (2007) 1312-1315. (Article of Interest)